SI1573335T1 - Cvd test - Google Patents

Cvd test

Info

Publication number
SI1573335T1
SI1573335T1 SI200331123T SI200331123T SI1573335T1 SI 1573335 T1 SI1573335 T1 SI 1573335T1 SI 200331123 T SI200331123 T SI 200331123T SI 200331123 T SI200331123 T SI 200331123T SI 1573335 T1 SI1573335 T1 SI 1573335T1
Authority
SI
Slovenia
Prior art keywords
calprotectin
antibody
assay
cvd
body fluid
Prior art date
Application number
SI200331123T
Other languages
English (en)
Slovenian (sl)
Inventor
Erling Axis-Shield Sundrehagen
Original Assignee
Axis Shield Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axis Shield Asa filed Critical Axis Shield Asa
Publication of SI1573335T1 publication Critical patent/SI1573335T1/sl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346Nanoparticles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4727Calcium binding proteins, e.g. calmodulin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Optical Head (AREA)
  • Gyroscopes (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SI200331123T 2002-12-20 2003-12-22 Cvd test SI1573335T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0229747.1A GB0229747D0 (en) 2002-12-20 2002-12-20 Assay
EP03786143A EP1573335B1 (de) 2002-12-20 2003-12-22 Cvd-assay
PCT/GB2003/005607 WO2004057341A2 (en) 2002-12-20 2003-12-22 Cvd assay

Publications (1)

Publication Number Publication Date
SI1573335T1 true SI1573335T1 (sl) 2008-04-30

Family

ID=9950111

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331123T SI1573335T1 (sl) 2002-12-20 2003-12-22 Cvd test

Country Status (16)

Country Link
US (3) US10101325B2 (de)
EP (2) EP1573335B1 (de)
JP (2) JP4653492B2 (de)
CN (3) CN1729398B (de)
AT (2) ATE427498T1 (de)
AU (1) AU2003295142A1 (de)
CA (2) CA2504876A1 (de)
DE (2) DE60317931T2 (de)
DK (2) DK1739430T3 (de)
ES (2) ES2323475T3 (de)
GB (1) GB0229747D0 (de)
NO (1) NO20052161L (de)
PL (2) PL216385B1 (de)
PT (1) PT1573335E (de)
SI (1) SI1573335T1 (de)
WO (1) WO2004057341A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
DE602005025775D1 (de) 2004-07-23 2011-02-17 Aspenbio Pharma Inc Verfahren und vorrichtungen zur diagnose von appendizitis
US7659087B2 (en) 2004-07-23 2010-02-09 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
EP1862805A1 (de) * 2006-06-01 2007-12-05 University of Zürich Verwendung von MRP 8/14-Konzentrationen zur Unterscheidung von Personen mit akutem Koronarsyndromrisiko
CA2753886C (en) * 2009-03-02 2018-06-12 Catholic Healthcare West Diagnostic devices and methods of use
DK2427482T3 (da) * 2009-05-07 2020-03-02 Chreto Aps Method for purification of target polypeptides
US9574977B2 (en) * 2013-02-26 2017-02-21 Innova Prep Liquid to liquid biological particle concentrator with disposable fluid path
EP2511704A1 (de) 2011-04-13 2012-10-17 Immundiagnostik AG Testverfahren für intrinsisch akute Nierenverletzung
NO20110895A1 (no) * 2011-06-21 2012-12-24 Magne Fagerhol Kompetitive S100A9 immunoanalyser
ES2402457B2 (es) * 2011-10-19 2014-01-20 Universidade De Vigo Procedimiento para el diagnóstico de derrame pleural maligno mediante la determinación de la concentración de calprotectina en líquido pleural.
US9122968B2 (en) 2012-04-03 2015-09-01 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
US9594999B2 (en) 2012-04-03 2017-03-14 X-Card Holdings, Llc Information carrying card comprising crosslinked polymer composition, and method of making the same
AU2013315371A1 (en) * 2012-09-12 2015-04-09 Berg Llc Use of markers in the identification of cardiotoxic agents
EP2973236B1 (de) 2013-03-15 2019-01-09 X-Card Holdings, LLC Verfahren zur herstellung einer kernschicht für eine informationskarte und in diesem verfahren hergestellte produkte
KR102457657B1 (ko) * 2017-02-07 2022-10-21 리프스톤 비.브이. 무균성 해리로 인한 임플란트 관련 임플란트 교정 위험을 진단하기 위한 바이오마커
EP3385712A1 (de) 2017-04-03 2018-10-10 Gentian AS Verbessertes calprotectin-assay
CN111094978B (zh) * 2017-05-09 2024-05-28 免疫诊断股份公司 免疫比浊法测定钙结合蛋白s100家族成员的方法
CN108196066A (zh) * 2018-01-22 2018-06-22 安徽伊普诺康生物技术股份有限公司 一种测定钙防卫蛋白的试剂盒及其制备使用方法
CN111819577B (zh) 2018-03-07 2024-08-13 X卡控股有限公司 金属卡
CN115836223A (zh) * 2020-05-13 2023-03-21 北欧生物科技公司 钙防卫蛋白测定

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287202A (en) * 1978-05-26 1981-09-01 Horrobin David F Treatment and/or prophylaxis of spasms of coronary arteries
JPS55162059A (en) * 1979-06-05 1980-12-17 Mochida Pharmaceut Co Ltd Measuring method for antigen, antibody or their complex and measurement reagent kit
US4401765A (en) * 1981-09-01 1983-08-30 E. I. Du Pont De Nemours And Company Covalently bonded high refractive index particle reagents and their use in light scattering immunoassays
US4480042A (en) * 1981-10-28 1984-10-30 E. I. Du Pont De Nemours And Company Covalently bonded high refractive index particle reagents and their use in light scattering immunoassays
GB8318754D0 (en) * 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
JPS60139621A (ja) 1983-12-27 1985-07-24 Grelan Pharmaceut Co Ltd 抗血栓剤
JPS625970A (ja) 1985-03-15 1987-01-12 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤
EP0310361A3 (de) * 1987-09-30 1989-05-24 Beckman Instruments, Inc. Aus drei Verzahnungen bestehendes Konjugat und Verfahren zu seiner Verwendung
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
ATE139845T1 (de) * 1989-08-23 1996-07-15 Canon Kk Methode zur messung eines immunologisch aktiven materials und vorrichtung, die dazu geeignet ist
US5455160A (en) * 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
US5776348A (en) * 1995-02-07 1998-07-07 Massachusetts Institute Of Technology Mineral precipitation system and method for inhibiting mineral precipitate formation
ATE278964T1 (de) * 1996-11-01 2004-10-15 Magne K Fagerhol Verfahren zur proteinextraktion
EP2305235A1 (de) * 1997-04-02 2011-04-06 The Brigham And Women's Hospital, Inc. Verfahren zur Ermittlung der individualen Risikoprofile atherosklerotischen Erkrankungen
GB9816088D0 (en) * 1998-07-23 1998-09-23 Axis Biochemicals Asa System
AU5436499A (en) * 1998-08-20 2000-03-14 Axis Biochemicals Asa Assay method for cardiovascular disease
ATE497171T1 (de) * 1999-07-05 2011-02-15 Leuven K U Res & Dev Von willebrand-faktor-aktivitätsnachweis
AU782386C (en) 1999-08-31 2006-08-10 Brigham And Women's Hospital Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
FR2800636A1 (fr) * 1999-11-05 2001-05-11 Bio Merieux Particules composites, conjugues derives, leur procede de preparation et utilisations
US7011952B2 (en) * 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US20030059461A1 (en) * 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
WO2002018953A1 (fr) * 2000-08-29 2002-03-07 Kyowa Medex Co.,Ltd Reactifs et methode d'immunoessai d'agglutination fortement reproductible
JP2002318233A (ja) * 2001-04-19 2002-10-31 Shino Test Corp 測定対象物質の比濁法測定試薬及び測定対象物質の比濁法測定方法
DE60233301D1 (de) * 2001-05-04 2009-09-24 Biosite Inc Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
FR2872579B1 (fr) * 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
WO2007106781A2 (en) * 2006-03-10 2007-09-20 University Of Rochester Ecg-based differentiation of lqt1 and lqt2 mutation

Also Published As

Publication number Publication date
CN1729398B (zh) 2012-04-04
PL377476A1 (pl) 2006-02-06
PL216385B1 (pl) 2014-03-31
JP4653492B2 (ja) 2011-03-16
JP2006510895A (ja) 2006-03-30
PT1573335E (pt) 2007-12-21
ES2323475T3 (es) 2009-07-16
CA2729365A1 (en) 2004-07-08
DE60327007D1 (de) 2009-05-14
ES2297250T3 (es) 2008-05-01
DK1573335T3 (da) 2008-04-14
NO20052161L (no) 2005-07-19
ATE380345T1 (de) 2007-12-15
EP1739430A3 (de) 2007-01-17
NO20052161D0 (no) 2005-05-03
DE60317931D1 (en) 2008-01-17
US20110318847A1 (en) 2011-12-29
US20190049439A1 (en) 2019-02-14
GB0229747D0 (en) 2003-01-29
EP1739430B1 (de) 2009-04-01
PL394295A1 (pl) 2011-09-12
JP5744385B2 (ja) 2015-07-08
JP2010019849A (ja) 2010-01-28
US20060134705A1 (en) 2006-06-22
EP1573335B1 (de) 2007-12-05
EP1573335A2 (de) 2005-09-14
CN101893635A (zh) 2010-11-24
AU2003295142A1 (en) 2004-07-14
EP1739430A2 (de) 2007-01-03
ATE427498T1 (de) 2009-04-15
DK1739430T3 (da) 2009-07-13
DE60317931T2 (de) 2008-11-13
US10101325B2 (en) 2018-10-16
CN102608326A (zh) 2012-07-25
WO2004057341A2 (en) 2004-07-08
WO2004057341A3 (en) 2004-10-21
CA2729365C (en) 2018-09-18
CN101893635B (zh) 2014-04-09
CN1729398A (zh) 2006-02-01
CA2504876A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
NO20052161D0 (no) Analysemetode for hjerte-karsykdom
EP2538218A8 (de) Biochemische Marker zur Bewertung des CVD-Risikos
MY162697A (en) Methods, devices and kits for detecting or monitoring acute kidney injury
WO2009117510A3 (en) Multi-wavelength analyses of sol-particle specific binding assays
WO2010038974A3 (ko) 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트
NZ592552A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ATE497023T1 (de) Nanosensoren und entsprechende technologien
JP2012509477A5 (de)
WO2006047591A3 (en) Rapid microfluidic assay for analyte interactions
MX2009003572A (es) Metodos para reducir interferencia optica en un dispositivo de fluido.
WO2005073405A3 (en) Catalytic polynucleotide and its use for determination of analytes
DE60130919D1 (de) Durchflussvorrichtung, diagnostischer kit diese enthaltend und gebrauch für den nachweis von analyten in einer probe
CN103575875A (zh) 一种新的功能化金纳米棒免疫探针及金纳米棒生物芯片的制备方法及应用
ATE467128T1 (de) Kolloidale metallkonjugate
JP2009544971A5 (de)
RU2008130888A (ru) Мас-2вр как маркер для диагностики рака желудка
WO2006119262A3 (en) Detection of carbohydrate biomarkers
CA2434694A1 (en) Detection and quantification of cripto-1
DE60332479D1 (de) Holo-transcobalamin bindungspartner und ihre verwendung in cobalamintest
WO2006044888A3 (en) Reagents for urine-based immunological assays
WO2005031365A3 (en) Rapid determination of hepatocyte growth factor (hgf) in the body fluids
Li et al. Flow sandwich immunoassay for specific anti-OVA IgG antibody by use of surface plasmon resonance sensor
ATE520985T1 (de) Verfahren zur bestimmung von antigen und antikörper gegen das antigen
WO2007122373A8 (en) Method for assaying antigens
WO2008067006A3 (en) A method for quantitative detection of diabetes related immunological markers